LeeAnn T. Marcello

Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse posttransplant

Susan DeWolf, Jason Kuttiyara, Paola Vinci, Teng Fei et autres

ABSTRACT: The bone marrow represents the tumor microenvironment for many hematologic malignancies and a potentially critical site for alloimmunity after hematopoietic transplantation. Despite the importance of immune reconstitution (IR) after transplant, marrow IR data are limited, and insights are largely derived from …

us (code pays fourni par la source)

Data from Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies

David J. Chung, Gunjan L. Shah, Sean M. Devlin, Lakshmi V. Ramanathan et autres

Abstract Coronavirus disease-19 (COVID-19) vaccine response data for patients with hematologic malignancy, who carry high risk for severe COVID-19 illness, are incomplete. In a study of 551 hematologic malignancy patients with leukemia, lymphoma, and multiple myeloma, anti–SARS-CoV-2 spike IgG titers and neutralizing …

us (code pays fourni par la source)

Data from Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Roni Tamari, Ioannis Politikos, David A. Knorr, Santosha Adipudi Vardhana et autres

Abstract Cellular therapies including allogeneic hematopoietic cell transplant (allo-HCT) and autologous hematopoietic cell transplant (auto-HCT) and chimeric antigen receptor (CAR) T-cell therapy render patients severely immunocompromised for extended periods after therapy, and data on responses to COVID-19 vaccines are limited. We analyzed …

us (code pays fourni par la source)

Data from Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Roni Tamari, Ioannis Politikos, David A. Knorr, Santosha Adipudi Vardhana et autres

Abstract Cellular therapies including allogeneic hematopoietic cell transplant (allo-HCT) and autologous hematopoietic cell transplant (auto-HCT) and chimeric antigen receptor (CAR) T-cell therapy render patients severely immunocompromised for extended periods after therapy, and data on responses to COVID-19 vaccines are limited. We analyzed …

Data from Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies

David J. Chung, Gunjan L. Shah, Sean M. Devlin, Lakshmi V. Ramanathan et autres

Abstract Coronavirus disease-19 (COVID-19) vaccine response data for patients with hematologic malignancy, who carry high risk for severe COVID-19 illness, are incomplete. In a study of 551 hematologic malignancy patients with leukemia, lymphoma, and multiple myeloma, anti–SARS-CoV-2 spike IgG titers and neutralizing …

Supplemental Table 1 from Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Roni Tamari, Ioannis Politikos, David A. Knorr, Santosha Adipudi Vardhana et autres

<50>50 Anti-SARS-CoV-2 spike IgG, <30>30 Neutralizing antibodies

Supplemental Table 2A&2B from Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Roni Tamari, Ioannis Politikos, David A. Knorr, Santosha Adipudi Vardhana et autres

2A- MVA for the whole cohort 2B-MVA for patients who underwent allo-HCT only

Supplemental Table 3A&3B from Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Roni Tamari, Ioannis Politikos, David A. Knorr, Santosha Adipudi Vardhana et autres

3A: Anti-SARS-CoV-2 spike IgG titers by different cutoffs Supplemental Table 3B: Neutralization Ab >30% threshold when using different cutoffs of anti-SARS-CoV-2 spike IgG response

Supplementary Table and Figures from Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies

David J. Chung, Gunjan L. Shah, Sean M. Devlin, Lakshmi V. Ramanathan et autres

Figures S1- S4

Supplemental Table 1 from Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Roni Tamari, Ioannis Politikos, David A. Knorr, Santosha Adipudi Vardhana et autres

<50>50 Anti-SARS-CoV-2 spike IgG, <30>30 Neutralizing antibodies

Supplemental Table 3A&3B from Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Roni Tamari, Ioannis Politikos, David A. Knorr, Santosha Adipudi Vardhana et autres

3A: Anti-SARS-CoV-2 spike IgG titers by different cutoffs Supplemental Table 3B: Neutralization Ab >30% threshold when using different cutoffs of anti-SARS-CoV-2 spike IgG response

Supplemental Table 2A&2B from Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Roni Tamari, Ioannis Politikos, David A. Knorr, Santosha Adipudi Vardhana et autres

2A- MVA for the whole cohort 2B-MVA for patients who underwent allo-HCT only